New hope: Chemo-Free cocktail targets advanced colorectal cancer

NCT ID NCT07257653

Recruiting now Disease control Sponsor: Zhejiang University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a combination of targeted drugs (cetuximab beta and fruquintinib) with or without immunotherapy can control advanced colorectal cancer without traditional chemotherapy. About 70 people with a specific genetic type (RAS/BRAF wild-type) will receive these drugs as their first treatment. The goal is to see if this approach can delay cancer growth and improve survival while avoiding chemotherapy side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL NEOPLASMS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal adenocarcinoma colorectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BRAF CETUXIMAB COLORECTAL NEOPLASMS FRUQUINTINIB RAS

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Second Affiliated Hospital Zhejiang University College of Medicine, Hangzhou, Zhejiang Province 310999
RECRUITING

Hangzhou, Zhejiang, China

Contact Phone: •••-•••-•••• Email: •••••@•••••